Φορτώνει......
NIMG-72. CEREBRAL BLOW FLOW AND SUV TRENDS IN PET/MRI FOLLOWING BEVACIZUMAB ADMINISTRATION IN GLIOBLASTOMA
BACKGROUND: Bevacizumab (BEV) is an antibody directed at vascular endothelial growth factor (VEGF) and holds FDA approval in recurrent glioblastoma (GBM). Pseudoprogression with necrosis is a common clinical concern in GBM, and BEV is useful in treating both tumor and necrosis. Though conventionally...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Neuro Oncol |
|---|---|
| Κύριοι συγγραφείς: | , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Oxford University Press
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5693070/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.644 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|